Farxiga (dapagliflozin) can improve kidney and metabolic outcomes in adolescents and young adults with Type 1 diabetes (T1D), according to a recent study published in Nature Medicine .

Type 1 diabetes is an autoimmune disease where the immune system destroys insulin-producing beta cells in pancreatic islets. Insulin helps the body use glucose for energy, and glucagon is released when glucose levels become too low. About 2 million Americans have Type 1 diabetes.

Developed by AstraZeneca, Farxiga is approved for several indications, including to reduce the risk of heart failure in patients with Type 2 diabetes, to reduce the risk of chronic kidney disease, to improve glycemia control in those with Type 2 diabetes, and to reduce the risk of cardiovascular death in patients with heart fa

See Full Page